Stem cells aim to calm the immune attack in scleroderma
NCT ID NCT07535931
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a stem cell injection (HS_SW01) in 21 adults with systemic sclerosis, a disease where the immune system attacks the body, causing skin hardening and organ damage. The main goal is to see if the treatment is safe and tolerable. Researchers will also check how the body processes the cells and whether they improve skin thickness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new pill ease the hardening skin of systemic sclerosis?
- A drug after transplant may stop scleroderma from coming back
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.